Wei Zhou

Wei Zhou is currently the Director of Cell Line Development at BioAtla LLC, where they oversee the development of cell lines for monoclonal and bispecific antibodies. They have extensive experience in protein expression, particularly with monoclonal antibodies, and in CHO cell line generation. Wei previously held positions such as Senior Scientist and Scientific Director at Promosome LLC, where they conducted significant research into monoclonal antibody expression and genome modification using CRISPR technology. Additionally, they have worked as a Postdoctoral Fellow at The Scripps Research Institute, focusing on signal transduction and translation enhancer identification. Wei is pursuing a Ph.D. in Cell and Molecular Biology at Baylor College of Medicine and holds a B.S. in Biochemistry from Fudan University.